Autor(es):Mostrar menos -

Johannsen, Sandra ; Gierse, Robin M. ; Kru''ger, Arne ; Edwards, Rachel L. ; Nanna, Vittoria ; Fontana, Anna ; Zhu, Di ; Masini, Tiziana ; de Carvalho, Lais Pessanha ; Poizat, Mael ; Kieftenbelt, Bart ; Hodge, Dana M. ; Alvarez, Sophie ; Bunt, Daan ; Lacour, Antoine ; Shams, Atanaz ; Meissner, Kamila Anna ; de Souza, Edmarcia Elisa ; Dro''ge, Melloney ; van Vliet, Bernard ; den Hartog, Jack ; Hutter, Michael C. ; Held, Jana ; Odom John, Audrey R. ; Wrenger, Carsten ; Hirsch, Anna K. H.

• Tipo de documento: Artigo Científico
• Fonte: ACS INFECTIOUS DISEASES; v. 10, n. 3, p. 23-pg., 2024-02-17.

Resumo

In this study, we identified three novel compound classes with potent activity against Plasmodium falciparum, the most dangerous human malarial parasite. Resistance of this pathogen to known drugs is increasing, and compounds with different modes of action are urgently needed. One promising drug target is the enzyme 1-deoxy-d-xylulose-5-phosphate synthase (DXPS) of the methylerythritol 4-phosphate (MEP) pathway for which we have previously identified three active compound classes against Mycobacterium tuberculosis. The close structural similarities of the active sites of the DXPS enzymes of P. falciparum and M. tuberculosis prompted investigation of their antiparasitic action, all classes display good cell-based activity. Through structure-activity relationship studies, we increased their antimalarial potency and two classes also show good metabolic stability and low toxicity against human liver cells. The most active compound 1 inhibits the growth of blood-stage P. falciparum with an IC50 of 600 nM. The results from three different methods for target validation of compound 1 suggest no engagement of DXPS. All inhibitor classes are active against chloroquine-resistant strains, confirming a new mode of action that has to be further investigated. (AU)

• Processo FAPESP: 18/08820-0 - Inibidores da via de síntese de vitamina B6 entregues por associação com nanopartículas contra Plasmodium sp
• Beneficiário: Arne Kruger
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 15/26722-8 - Drug discovery contra doenças infecciosas humanos
• Beneficiário: Carsten Wrenger
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/03966-4 - Alvejando a via de recuperação e biossíntese de ácido lipoico em MRSA
• Beneficiário: Carsten Wrenger
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/24790-9 - Validação da importância de PfEXP1/GST2 para defesa contra xenobióticos em modelos de deficiência de glicose-6-fosfato desidrogenase infectados com Plasmodium Falciparum
• Beneficiário: Kamila Anna Meissner
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 20/12277-0 - Drug discovery contra doenças infecciosas humanas
• Beneficiário: Edmarcia Elisa de Souza
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado